Welcome to our dedicated page for NextCure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextCure, Inc. filings document a clinical-stage oncology issuer's financial reporting, governance, capital structure, and material-event disclosures. Recent Form 8-K reports furnish quarterly and annual results, business update exhibits, Regulation FD materials on ADC programs, officer transition disclosure, a completed private placement of common stock and pre-funded warrants, and an effected reverse stock split.
The company's proxy materials cover annual meeting matters including director elections, auditor ratification, say-on-pay, board governance, and executive compensation for a Delaware corporation with Nasdaq-listed common stock.
Form 4 filing overview
On 24 June 2025, NextCure, Inc. (NXTC) reported that director Anne Elizabeth Borgman was granted a stock option for 18,700 common shares at an exercise price of $0.47 per share. The grant date was 20 June 2025 (transaction code “A”). The option vests in full on the earlier of 20 June 2026 or the 2026 annual shareholders’ meeting and carries an expiration date of 19 June 2035.
No open-market acquisitions or dispositions of common stock were disclosed, and the director’s post-transaction beneficial holding consists of 18,700 derivative securities held directly. Because this is a routine equity-incentive award rather than a purchase or sale, immediate valuation impact is minimal, but the disclosure illustrates continued use of option grants to align board incentives with shareholder interests.
NextCure director Stephen W. Webster received a stock option grant on June 20, 2025, representing a significant insider transaction. Key details include:
- Granted 18,700 stock options to purchase common stock
- Exercise price set at $0.47 per share
- Options expire on June 19, 2035
- Full vesting occurs on the earlier of June 20, 2026 or the 2026 Annual Meeting
This director compensation grant suggests continued board engagement and alignment with shareholder interests through equity-based incentives. The relatively low exercise price compared to typical market prices for biotech stocks may indicate current market challenges or strategic considerations in retention of board talent.
NextCure, Inc. (NXTC) – Form 4 insider filing
On 24 June 2025, director Ellen Feigal filed a Form 4 reporting the grant of a stock option on 20 June 2025. The option covers 18,700 shares of common stock at an exercise price of $0.47 per share. It vests in full on the earlier of 20 June 2026 or the date of NextCure’s 2026 Annual Meeting of Stockholders and carries an expiration date of 19 June 2035. Ownership is reported as direct.
No open-market purchases or sales of common shares were disclosed, and no additional derivative or non-derivative transactions were listed. After the grant, Dr. Feigal’s beneficial ownership consists solely of these 18,700 option shares.
The filing represents a routine equity incentive award to a director and does not convey new operational or financial performance data.